CleanCap® enables a high-yield, streamlined manufacturing process that is cell-free and highly scalable for mRNA-based therapeutic and vaccine development. Unlike legacy methods, CleanCap offers a ...

SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- TriLink BioTechnologies (TriLink), a Maravai LifeSciences (MRVI) company and global provider of life science reagents and services, has launched its newest ...

SAN DIEGO--(BUSINESS WIRE)--TriLink BioTechnologies (TriLink®), a Maravai® LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has signed a non-exclusive ...

New all-in-one IVT kit can deliver up to 2X more mRNA and up to 85% lower dsRNA compared to other kits on the market through streamlined mRNA synthesis with efficient capping, increased yield, reduced ...

Enabling the future development of critical therapeutics, Aldevron customers now have access to TriLink’s CleanCap mRNA capping technology for non-commercial use SAN DIEGO, February 04, ...

TriLink’s CleanCap technology produces optimal 5′ cap structures with over 95% efficiency, creating a co-transcriptional capping solution that dramatically improves mRNA yield and process time when ...

Lonza customers can now access TriLink’s CleanCap ® mRNA capping technology for non-commercial use, enabling further development of critical mRNA therapeutics SAN DIEGO, April 30, 2024--(BUSINESS WIRE ...

The donation commemorates the launch of TriLink’s first mRNA synthesis kit featuring CleanCap® capping technology, an all-in-one kit with its innovative products in one box at a competitive price.

TriLink BioTechnologies (TriLink), a Maravai LifeSciences company and global provider of life science reagents and services, has signed a non-exclusive license and supply agreement with Aldevron, a ...